ERBB2 and breast carcinoma: The NeoSPHERE trial studied the efficacy and safety of neoadjuvant pertuzumab and/or trastuzumab plus or minus a taxane in women with early or advanced HER2-positive breast cancer and tested four arms: (A) trastuzumab plus docetaxel, (B) pertuzumab and trastuzumab plus docetaxel, (C) pertuzumab and trastuzumab, and (D) pertuzumab plus docetaxel68.